William Blair Forecasts Increased Earnings for Neuronetics

Neuronetics, Inc. (NASDAQ:STIM) – Equities research analysts at William Blair boosted their Q1 2025 EPS estimates for Neuronetics in a research report issued to clients and investors on Wednesday, March 5th. William Blair analyst M. Andrew now forecasts that the company will post earnings of ($0.15) per share for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Neuronetics’ current full-year earnings is ($1.13) per share. William Blair also issued estimates for Neuronetics’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.33) EPS.

Separately, Canaccord Genuity Group boosted their price objective on shares of Neuronetics from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday.

Neuronetics Stock Down 8.5 %

Shares of NASDAQ STIM opened at $4.96 on Friday. The stock has a market capitalization of $150.53 million, a P/E ratio of -4.03 and a beta of 2.07. The stock’s fifty day moving average is $3.06 and its 200 day moving average is $1.70. Neuronetics has a 52 week low of $0.52 and a 52 week high of $5.92. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Institutional Investors Weigh In On Neuronetics

Several hedge funds and other institutional investors have recently bought and sold shares of STIM. Tradewinds LLC. bought a new stake in Neuronetics during the 4th quarter valued at $32,000. XTX Topco Ltd bought a new position in shares of Neuronetics during the 4th quarter worth approximately $49,000. David J Yvars Group increased its position in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after purchasing an additional 14,825 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock worth $88,000 after buying an additional 54,442 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in Neuronetics in the third quarter worth about $53,000. 53.59% of the stock is owned by institutional investors.

Insider Buying and Selling at Neuronetics

In other news, CFO Stephen Furlong sold 14,836 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $48,662.08. Following the completion of the transaction, the chief financial officer now directly owns 482,572 shares in the company, valued at $1,582,836.16. This trade represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Keith J. Sullivan sold 40,992 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $134,453.76. Following the completion of the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at $4,209,427.36. This trade represents a 3.10 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 100,369 shares of company stock worth $358,929. 9.80% of the stock is currently owned by company insiders.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.